☆ 4.6 Article

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus

VETERINARY SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Analytical

Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101

Chun-Hao Chang et al.

Summary: The aim of this study was to investigate the effects of herbal drug interactions on the biotransformation of molnupiravir and its metabolite NHC in the blood and brain. The results showed that molnupiravir was rapidly metabolized to NHC and penetrated into the brain.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)

Add to Collection

Article Veterinary Sciences

Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524

Jodie Green et al.

Summary: This study investigates the use of a combination of oral GS-441524 and injectable remdesivir for the treatment of feline infectious peritonitis (FIP) in cats. The results show that 87.5% of cats responded to treatment within 2 days, and 81.3% of cats were alive and in remission at the end of the 12-week treatment period. However, 18.8% of cats died or were euthanized during treatment. These findings suggest that the combination of injectable remdesivir and oral GS-441524 is effective for treating FIP.

JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)

Add to Collection

Article Veterinary Sciences

Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524

Sally J. Coggins et al.

Summary: This study aimed to evaluate the efficacy and tolerability of the therapeutic drugs GS-441524 and its prodrug remdesivir (GS-5734) for feline infectious peritonitis (FIP). The results showed that intravenous administration of remdesivir and oral administration of GS-441524 were effective and well-tolerated treatments for FIP. When monitoring treatment efficacy, early emphasis on clinical response and later emphasis on clinicopathologic response appear to be prudent.

JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis

Wen Wen et al.

Summary: This study conducted a meta-analysis on three new oral antivirals (molnupiravir, fluvoxamine, and Paxlovid) and their effects on mortality and hospitalization rates among COVID-19 patients. The results showed that these drugs were effective in reducing mortality and hospitalization rates by approximately 67%. Furthermore, the drugs did not increase adverse events, indicating good overall safety.

ANNALS OF MEDICINE (2022)

Add to Collection

Article Veterinary Sciences

Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro

Sarah E. Cook et al.

Summary: This study identified 26 compounds with effective antiviral activity against FIPV through in vitro screening, including a variety of drug classes and mechanisms of antiviral action. The most effective compounds were GC376, GS-441524, EIDD2081, and EIDD2931. Combinations of antiviral agents also showed some evidence of limited synergistic antiviral activity.

JOURNAL OF FELINE MEDICINE AND SURGERY (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Chemistry, Medicinal

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models

Yingjun Li et al.

Summary: The article reports that the parent nucleoside of remdesivir, GS-441524, shows potent inhibition of SARS-CoV-2 replication and has high efficacy in reducing viral titers in infected organs without notable toxicity in animal studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Cell Biology

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

William A. Fischer et al.

Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Chemistry, Medicinal

Novel Nitrile Peptidomimetics for Treating COVID-19

C. S. Brian Chia

ACS Medicinal Chemistry Letters (2022)

Add to Collection

Article Pharmacology & Pharmacy

Nirmatrelvir Plus Ritonavir: First Approval

Yvette N. Lamb

Summary: Nirmatrelvir plus ritonavir is a medication developed for the treatment and post-exposure prophylaxis of COVID-19. It received authorization in the UK and EU for use in adults at high risk for severe COVID-19. Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease, while ritonavir is a protease inhibitor and CYP3A inhibitor.

DRUGS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™

Jean G. Sathish et al.

Summary: SARS-CoV-2 3CL protease (Mpro) is a key enzyme for the replication of COVID-19, and nirmatrelvir is its target. Paxlovid (nirmatrelvir co-administered with ritonavir) has shown efficacy in treating high-risk COVID-19 patients. Nonclinical safety studies of nirmatrelvir support its clinical development and use in the treatment of COVID-19.

INTERNATIONAL JOURNAL OF TOXICOLOGY (2022)

Add to Collection

Article Virology

Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors

Zhe Jiao et al.

Summary: The development of antiviral drugs is crucial in addressing the rapidly emerging SARS-CoV-2. This study explores the resistance mutations of the viral main protease (M-pro) and identifies the impact of these mutations on viral replication and drug resistance. The findings highlight the need for a combination therapy to effectively combat contemporary and emerging coronaviruses.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

Ronen Arbel et al.

Summary: The study showed that among patients aged 65 years or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir compared to those who did not. However, no evidence of benefit was found in younger adults.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Virology

An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats

Sarah Cook et al.

Summary: Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks effective vaccines or treatments. This study aimed to determine and compare the antiviral efficacies of several drugs in vitro and evaluate their pharmacokinetic properties. The results showed that certain drug combinations exhibited synergy against FIPV, the causative agent of FIP.

VIRUSES-BASEL (2022)

Add to Collection

Article Microbiology

Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis

Meagan Roy et al.

Summary: Feline infectious peritonitis (FIP) is a fatal disease, but recent advancements in antiviral therapy, such as the use of unlicensed molnupiravir, have shown potential as safe and effective treatments for FIP.

PATHOGENS (2022)

Add to Collection

Letter Virology

On the Calculation of TCID50 for Quantitation of Virus Infectivity

Chengfeng Lei et al.

VIROLOGICA SINICA (2021)

Add to Collection

Article Microbiology

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Wendy P. Painter et al.

Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl et al.

Summary: The study suggests that bats may be the source of coronaviruses that can be directly transmitted to humans. Using the LoM model, efficient replication of SARS-CoV, MERS-CoV, SARS-CoV-2, and two SARS-like bat coronaviruses in human lung tissue was demonstrated. Infection with SARS-CoV-2 predominantly targets human lung epithelial cells and induces a sustained inflammatory response. The broad-spectrum antiviral agent EIDD-2801 significantly inhibits SARS-CoV-2 replication in vivo, showing potential for prevention and treatment of COVID-19.

NATURE (2021)

Add to Collection

Review Microbiology

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses

Judith M. White et al.

Summary: The world was unprepared for COVID-19 and needs to develop pan-family drug cocktails for future pandemics, focusing on enhancing potency, limiting toxicity, and avoiding drug resistance. The article emphasizes the importance of expedited clinical trials testing drug combinations that could be taken at home by infected individuals and exposed contacts in early stages of the next pandemic.

MBIO (2021)

Add to Collection

Article Immunology

β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Shuntai Zhou et al.

Summary: Mutagenic ribonucleosides can serve as broad-spectrum antiviral agents, but may pose risks to the host due to their host mutagenic activity in addition to antiviral activity.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Virology

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection

Koen Vandyck et al.

Summary: This article reviews first-generation SARS-CoV-2 3CLpro inhibitors PF-07304814, GC-376, and CDI-45205, which are currently being delivered either by injection or inhalation due to their low intrinsic oral bioavailability. Additionally, PF-07321332 is emerging as a promising second-generation clinical candidate for oral delivery. A key challenge in the development of novel 3CLpro inhibitors is the poor understanding of the predictive value of in vitro potency towards clinical efficacy, complicated by the involvement of host proteases in virus entry. Further preclinical and clinical validation will be crucial in establishing 3CLpro inhibitors as a bona fide class for future SARS-CoV-2 therapeutics for both hospitalized and outpatient populations.

CURRENT OPINION IN VIROLOGY (2021)

Add to Collection

Article Oncology

The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Andreas Neubauer et al.

Summary: The study showed that the use of ruxolitinib in ARDS patients induced by COVID-19 may be feasible and effective. Early initiation of ruxolitinib was associated with better outcomes.

LEUKEMIA (2021)

Add to Collection

Letter Clinical Neurology

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series

Geraldine Luetic et al.

Summary: The study reported the COVID-19 outcomes in multiple sclerosis patients treated with teriflunomide in Argentina, showing that the infection was mild in these patients, and continuing with teriflunomide treatment did not lead to MS relapses.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Agriculture, Dairy & Animal Science

Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis

Sarah Jones et al.

Summary: The study evaluated the use of unlicensed GS-441524-like antiviral therapy in treating cats suspected of FIP. The majority of owners were from the United States, with only a small percentage receiving help from veterinarians. While the treatment cost was high, most owners reported significant improvement within one week, with majority of cats surviving and being cured, despite some relapses and deaths. Reported complications were mainly related to owner administration of injections.

ANIMALS (2021)

Add to Collection

Article Cell Biology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Veterinary Sciences

Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis

Peter J. Dickinson et al.

JOURNAL OF VETERINARY INTERNAL MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

B. Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi et al.

JOURNAL OF NEUROLOGY (2020)

Add to Collection

Article Chemistry, Medicinal

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

Victoria C. Yan et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Add to Collection

Article Immunology

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia

Maria Rosa Ciardi et al.

JOURNAL OF NEUROIMMUNOLOGY (2020)

Add to Collection

Letter Oncology

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

Alessandro Gozzetti et al.

LEUKEMIA (2020)

Add to Collection

Article Veterinary Sciences

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

Niels C. Pedersen et al.

JOURNAL OF FELINE MEDICINE AND SURGERY (2019)

Add to Collection

Article Veterinary Sciences

Cross-sectional quantitative RT-PCR study of feline coronavirus viremia and replication in peripheral blood of healthy shelter cats in Southern California

Eric J. Fish et al.

JOURNAL OF FELINE MEDICINE AND SURGERY (2018)

Add to Collection

Article Veterinary Sciences

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Niels C. Pedersen et al.

JOURNAL OF FELINE MEDICINE AND SURGERY (2018)

Add to Collection

Article Microbiology

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies

B. G. Murphy et al.

VETERINARY MICROBIOLOGY (2018)

Add to Collection

Article Microbiology

Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

Yunjeong Kim et al.

PLOS PATHOGENS (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Genotyping coronaviruses associated with feline infectious peritonitis

Catherine S. Lewis et al.

JOURNAL OF GENERAL VIROLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Veterinary Sciences

An update on feline infectious peritonitis: Diagnostics and therapeutics

Niels C. Pedersen

VETERINARY JOURNAL (2014)

Add to Collection

Article Medicine, General & Internal

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Veterinary Sciences

Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus

DD Addie et al.

VETERINARY RECORD (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.